UBS Group
INSY

UBS Group’s Insys Therapeutics, Inc. INSY Stock Holding History

UBS Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-200
Closed -$6K – 9036
2015
Q1 		$6K Sell
200
-1,600
-89% -$42.3K ﹤0.01% 8041
2014
Q4 		$38K Buy
+1,800
New +$35.6K ﹤0.01% 6836

Other funds holding INSY

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

UBS Group's INSY Position: Q2 2019 in Review

UBS Group sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 34,071 shares — an estimated $158K sold.

UBS Group first reported a position in INSY in Q4 2014 and held it in 18 quarters. The position peaked at $3.65M in Q4 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • UBS Group reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • UBS Group sold 34,071 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $158K.
  • UBS Group first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 18 quarters.
  • UBS Group's Insys Therapeutics, Inc. position peaked at $3.65M in Q4 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.